Engineering flaw may render cancer vaccines ineffective

Some cancer vaccines may be ineffective because of an engineering flaw in the vaccine's design, a study has found. Research performed at Texas MD Anderson Cancer Center and published in Nature Medicine examined the T cell responses elicited in mice after vaccination with the cancer vaccine gp100 melanoma peptide. The aim of the cancer immunotherapy is to increase the levels …